CRISPR

CRISPR1-smarca5

ID

ZDB-CRISPR-180213-390

Name

CRISPR1-smarca5

Previous Names

None

Target

smarca5 (1)

Sequence

5' - GGACCTGCTGGGTGGATATG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "AGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zko1049a	smarca5
zko1049b	smarca5

Expression

Gene expression in Wild Types + CRISPR1-smarca5

No data available

Phenotype

Phenotype resulting from CRISPR1-smarca5

No data available

Phenotype of all Fish created by or utilizing CRISPR1-smarca5

Phenotype	Fish	Conditions	Figures
caudal vein plexus blood coagulation, fibrin clot formation increased frequency, ameliorated	smarca5^{zko1049a/zko1049a}	chemical treatment by environment: argatroban	Figure 2 from Ding et al., 2021
nucleate erythrocyte fbp1a expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
thymus rag1 expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Fig. 3 from Ding et al., 2020
nucleate erythrocyte gsto2 expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
nucleate erythrocyte keap1a expression decreased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
nucleate erythrocyte pgd expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
myeloid cell spi1b expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Fig. 3 from Ding et al., 2020
caudal vein plexus blood coagulation, fibrin clot formation increased frequency, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 1 from Ding et al., 2021
erythroid lineage cell gata1a expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Fig. 3 from Ding et al., 2020
caudal vein plexus tal1 expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 1 from Ding et al., 2021
nucleate erythrocyte hmox1a expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
nucleate erythrocyte gstp1.2 expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
nucleate erythrocyte g6pd expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 6 from Ding et al., 2021
lymphoid progenitor cell rag1 expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Fig. 3 from Ding et al., 2020
nucleate erythrocyte mitochondrial crista damaged, abnormal	smarca5^{zko1049a/zko1049a}	standard conditions	Figure 3 from Ding et al., 2021
nucleate erythrocyte cellular response to oxidative stress increased rate, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg	standard conditions	Figure 4 from Ding et al., 2021
nucleate erythrocyte apoptotic process increased rate, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg	standard conditions	Figure 4 from Ding et al., 2021
nucleate erythrocyte cellular senescence increased rate, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg	standard conditions	Figure 4 from Ding et al., 2021
nucleate erythrocyte chromatin remodeling disrupted, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg	standard conditions	Figure 5 from Ding et al., 2021
nucleate erythrocyte inflammatory response increased rate, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg	standard conditions	Figure 4 from Ding et al., 2021
nucleate erythrocyte DsRed expression spatial pattern, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg; y1Tg/y1Tg	standard conditions	Figure 1 from Ding et al., 2021
nucleate erythrocyte DsRed expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg; y1Tg/y1Tg	standard conditions	Figure 1 from Ding et al., 2021
caudal vein plexus blood coagulation, fibrin clot formation increased frequency, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg; y1Tg/y1Tg	standard conditions	Figure 2 from Ding et al., 2021
caudal vein plexus DsRed expression increased amount, abnormal	smarca5^{zko1049a/zko1049a}; sd2Tg/sd2Tg; y1Tg/y1Tg	standard conditions	Figure 2 from Ding et al., 2021
caudal hematopoietic tissue myb expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}; zf3609Tg	standard conditions	Fig. 6 from Ding et al., 2020
caudal vein plexus blood coagulation, fibrin clot formation increased frequency, ameliorated	smarca5^{zko1049a/zko1049a} + MO2-hmox1a	standard conditions	Figure 6 from Ding et al., 2021
caudal hematopoietic tissue myb expression decreased distribution, abnormal	smarca5^{zko1049a/zko1049a}; ioz119Tg	control	Fig. 3 from Ding et al., 2020

Citations